WATERTOWN, MA, Neumora Therapeutics announced its launch today with $500 million in equity.
Neumora Therapeutics, a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, announced its launch today. Neumora was founded as a response to the lack of targeted, effective medicines for brain diseases and the high failure rate that has plagued neuroscience drug development for decades.
Over $500 million in capital has been raised, including a $100 million equity investment and strategic collaboration with Amgen announced separately today; Series A financing led by ARCH Venture Partners with participation from leading investors.
Neumora Therapeutics is a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Neumora is redefining neuroscience research and development with a data-driven precision neuroscience platform to cut through brain disease heterogeneity to match the right patient populations to targeted therapeutics. The Company's precision data science platform integrates multiple data types to define patient subtypes through the development of Data Biopsy Signatures and Precision Phenotypes. Neumora is relentless in its commitment to discovering, developing and commercializing targeted therapies for people living with brain diseases.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about